Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS: Vermillion Presents Critical Data From Its OVA1 Clinical Trial
9:00a ET February 10, 2009 (PR NewsWire)
Study Presented at Society of Gynecologic Oncologists' 40th Annual Meeting - on Women's Cancer
FREMONT, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (OTC Bulletin Board: VRML), a molecular diagnostics company, presented data from its prospective OVA1 clinical trial at the Society of Gynecologic Oncologists' (SGO) 40th Annual Meeting on Women's Cancer in San Antonio, TX (Poster 196). The study entitled "A biomarker panel for distinguishing between malignant and benign ovarian tumors" was co-authored by Fred Ueland, MD, Associate Professor of Gynecologic Oncology at the University of Kentucky and Principal Investigator of the OVA1 clinical trial, and Zhen Zhang, PhD, Associate Professor of Pathology at the Johns Hopkins University School of Medicine as well as Vermillion scientists.
Details of the poster are available in the attached link "A biomarker panel for distinguishing between malignant and benign ovarian tumors." The primary aim of the study was to determine the ability of our proprietary OvaCalc algorithm to estimate the risk of malignancy in pre and postmenopausal women who are scheduled for surgery with an ovarian mass. The data demonstrates that the OvaCalc algorithm can effectively identify women with a higher likelihood of malignancy. Within the study population, the OvaCalc algorithm also detected 90% of Stage I epithelial ovarian cancer cases and 100% of stage 2-4 cancers while maintaining a greater than 90% negative predictive value among both premenopausal and postmenopausal patients.
"We are extremely pleased with the significant results of the OVA1 prospective clinical trial. A major strength of the OVA1 prospective clinical trial was its inclusion of patients seen at a variety of clinical settings where the intended patient population typically undergoes a gynecological examination with radiological and clinical testing prior to surgical intervention. The 27 sites were demographically mixed to include, for example, large and small medical centers (universities/community hospitals), small gynecology/obstetrics groups, gynecology/oncology practices, and subjects from HMO groups. This study demonstrated with statistical significance the effectiveness of the OVA1 test in estimating the risk of malignancy in pre and postmenopausal women who are scheduled for surgery with an ovarian mass," said Gail S. Page, President and CEO.
"Research demonstrates that patients who have initial surgery performed by a gynecologic oncologist fare better than patients who are treated by a non-specialist. Any additional diagnostic tools that help the physician identify who is at a high risk of EOC may result in more optimal referral patterns and improved outcomes," said Karen Orloff Kaplan, Sc.D., Chief Executive Officer of the Ovarian Cancer National Alliance.
About Vermillion's Ovarian Cancer Diagnostic Program
Vermillion has multiple ovarian cancer diagnostic tests in development. The most advanced of Vermillion's programs is the OVA1 test, which is designed to utilize a panel of biomarkers to help identify women with a higher likelihood of malignancy so they can be referred to a gynecologic oncologist for their initial surgery. Vermillion filed a 510(K) Application with the U.S. Food and Drug Administration for its OVA1(TM) Test in June 2008.
Additionally, studies are underway to develop tests with the capability of detecting early-stage ovarian cancer, predicting prognosis and recurrence, and identifying women considered at high-risk for the disease.
Vermillion's premier diagnostic development program is being conducted with several leading collaborators at The Johns Hopkins School of Medicine, The University of Texas M.D. Anderson Cancer Center, Rigshospitalet (Copenhagen), and the University of Kentucky.
The Company's OVA1 test is part of a strategic alliance with Quest Diagnostics to jointly develop and commercialize diagnostic tests.
Stock back up to 0.74.
Whoever got in at 0.25, congratulations!
Is this heading for a reverse split?
Still nothing done on my .0002 GTC order. It's been almost a MONTH.
I just found this stock today. Can someone provide a link to news about why this is caveat emptor? I'm having trouble finding info.
16-fold dilution in shares outstanding = pps plummets
Where is the link to this information? Or is it just an opinion?
43.7 million traded, 10x over the 10 day average. PHEW!
52 week low today 0.25. This stock is due for a bounce back
I have 0001s and have been trying to sell just some 0002s for weeks (GTC) and nothing's been done. Be careful if you are thinking of doing a 0001 to 0002 flip. It may never happen, as it has yet to happen for me.
0.20 x 1.01 crazy spread
I can't go to 5th digit either. Tried. This stock has hit 0.0002 almost every day in the last two weeks, but my order remains un-filled. There must be a bagillion ahead :)
It was closed for 10 days by the SEC. Now it is open for trading again on the gray sheets. Your are right, no L2, no market makers' market.
I have a sell in at 0.0002. Been there for more than 2 weeks GTC with nothing done yet. I just want out of this one, but refuse to sell it at 0.0001. If someone can convince me to hold my shares for a valid reason, I'll cancel my order.
I'm still holding mine, as I wasn't around to sell mine when this stock re-opened. Now it isn't worth it to sell it with brockerage fees.
Yeah profit taking for those that got in at .0005-.0007
Maybe some profit taking at mid-day yesterday kept this from going higher. GLTA
ITEC up 150% on great news eom.
UP 150% today eom.
What's going on with this stock? Been down very sharply the last several days.
GTC questions.
1) Do GTC orders show up on Level 2?
2) If there is a GTC order for a certain price, but a day order comes in at same price after the GTC, does the GTC get executed first, or the day order?
At 0.0001 maybe? lol
Pink sheets says 205,958 shares outstanding for a market cap of $21. Are you saying pink sheets is incorrect?
Are there any diehard folks still holding onto their shares?
VRML up 100% today, light volume
VRML up 100% today, light volume
Up 100% today.
Delisting of VRML from NASDAQ
Comment: this was expected and many stocks are facing the same problem following the market plung in October and November.
Delisting of Securities of Vermillion, Inc. From The NASDAQ Stock Market
4:05p ET December 4, 2008 (GlobeNewswire)
The NASDAQ Stock Market announced today that it will delist the common stock of Vermillion, Inc. Vermillion, Inc.'s stock was suspended on September 25, 2008 and has not traded on NASDAQ since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after the Form 25 is filed. For news and additional information about the company, including the basis for the delisting and whether the company's securities are trading on another venue, please review the company's public filings or contact the company directly.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: The NASDAQ OMX Group, Inc.
For more information about The NASDAQ Stock Market, visit the NASDAQ Web site at http://www.nasdaq.com. NASDAQ's rules governing the delisting of securities can be found in the NASDAQ Rule 4800 Series, available on the NASDAQ Web site: http://www.cchwallstreet.com/NASDAQTools/bookmark.asp?id=nasdaq-rule_4800&manual=/nasdaq/main/nasdaq-equityrules/.
Triple normal volume today
You can't start a class action on the "possibility" of a scam. It would have to be clear that is was a scam with documented evidence.
And let's say for the sake of argument that you do have documented evidence of a scam. Class action lawsuit against a company that has no revenue will not likely lead to you getting your money back. Not to mention the expense of litigation.
0.30 x 1.01 spread has grown again.
Up 8% today on light volume
Does this stock have a chance to reverse split yet again before the end of the year? I hope not...
Web site links to wrong ticker symbol!
Click on
http://www.hattrickdrinks.com/investors.html
Then click on HKBV.PK- takes you not to HKBV but to MONA!
Anyone know when did this happened?
How many outstanding shares?
Pink sheets.com says 4,655,607 on 8/29/08, same day as the 1:100 reverse split. It seems like there are far more outstanding shares than this, as the market cap is now only $1,862 which doesn't make sense.
I have shares and I'm holding them tight.
Float= 5,660,120 shares
.45 x .60 Spread getting tighter
If SEC's suspension was inappropriate in the first place (i. e. HKBV has been telling the truth all along with their PRs), would the stock still stay grey, or would SEC have an obligation to move them back to pink status? It's just a scenario to discuss; I'm not saying SEC was wrong to suspend or anything.
Thanks for the explanation.
From .008 to ~0.02 in last 30 days
Market cap: $41.20. YIKES! eom
Is there any way for this stock to get off of the greys? If so, how do they go about doing that? And how long would it take?